Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Papillomavirus Infections 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1COVID-19 1

Interventions

Standard of Care 2tocilizumab 1selinexor 1lenzilumab 1cilgavimab and tixagevimab drug combination 1Practice Guidelines as Topic 1Observation 1Interferon-alpha 1Immunoglobulin G 1IMM-101 1Disulfides 1CVnCoV COVID-19 vaccine 1COVID-19 Vaccines 1BNT162 Vaccine 1Atorvastatin 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × COVID-19 × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡